ARQT News and Press, Arcutis Biotherapeutics Inc. From 07/11/22

Arcutis Biotherapeutics Reaches Regulatory Milestone with Health Canada Acceptance of New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis Canada NewsWire Submission supported by efficacy data from the pivotal Phase 3 DERMIS-1 an...

Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studies If approved, roflumilast cream would be the first and only topical PDE4 inhibitor for psoriasis in Canada Targ...

A Food and Drug Administration (FDA) approval for a highly anticipated treatment is the kind of news that can make a company's stock skyrocket, even during a bear market -- like the one we're in now. One company hoping for such success is Arcutis Biotherapeutics (NASDAQ: ARQT)...

Arcutis Biotherapeutics (NASDAQ:ARQT) said its medicine roflumilast foam helped reduce severity of a skin disease called seborrheic dermatitis, meeting the main goal of a late-stage study. Seborrheic dermatitis is a skin condition which mainly affects the scalp, causing scaly p...

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P<0.0001) More than 50% of patients treated with roflumilast foam achieved an IGA sc...

=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN) +17%. Abercrombie & Fitch (ANF) +17%. Losers: Verrica Pharmaceutica...

Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S. Survey found that, among adults with seborrheic dermatitis who use treatments, only one in four are very satisfied with the effectiveness of prescription treatments and o...

Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S. Survey found that, among adults with seborrheic dermatitis who use treatments, only one in four are very satisfied with the effectiveness of prescription treatments ...

Arcutis Biotherapeutics press release (NASDAQ:ARQT): Q1 GAAP EPS of -$1.27 beats by $0.22. The company believes that its current cash, cash equivalents, and marketable securities of $344.8M, combined with its committed loan facility, will be sufficient to fund its operations into 2024. For ...

Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and adolescents Completed enrollment of the sole pivotal Phase 3 trials of roflumilast foa...